NCT05833724 - Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 18, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Relapsed or Refractory Peripheral T-cell Lymphoma

Interventions

DRUG

Chidamide

Subjects will receive a single dose of 30 mg chidamide. Twice a week.

Trial Locations (5)

NOT_YET_RECRUITING

Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung City

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

NOT_YET_RECRUITING

Taichung Veterans General Hospital, Taichung

NOT_YET_RECRUITING

National Taiwan University Hospital, Taipei

NOT_YET_RECRUITING

Chang Gung Memorial Hospital, Linkou, Taoyuan District

All Listed Sponsors

lead

Great Novel Therapeutics Biotech & Medicals Corporation

INDUSTRY